ANALISIS EFEKTIFITAS TERAPI KOMBINASI ANTIPLATELET  ASPIRIN-CLOPIDOGREL DENGAN ASPIRIN-TICAGRELOR PADA PASIEN SINDROM KORONER AKUT: SYSTEMATIC LITERATURE REVIEW

Andrian Hoerul Anwar

doi:10.51225/jps.v8i2.84

Authors

Andrian Hoerul Anwar Universitas Islam Bandung

DOI:

https://doi.org/10.51225/jps.v8i2.84

Keywords:

Acute Coronary Syndrome, Aspirin-Clopidogrel, Aspirin-Ticagrelor, Antiplatelet

Abstract

Acute Coronary Syndrome (ACS) is one of the leading causes of cardiovascular morbidity and mortality, making dual antiplatelet therapy (DAPT) a crucial component of treatment. The combination of aspirin-clopidogrel has long been used, but its effectiveness is limited by genetic resistance, whereas aspirin-ticagrelor offers a faster and more consistent antiplatelet effect. This study aims to analyze the effectiveness and safety of both regimens through a Systematic Literature Review (SLR) by searching PubMed, Scopus, ScienceDirect, and Cochrane Library for articles published between 2015 and 2025. The results show that aspirin-ticagrelor is more effective in reducing Major Adverse Cardiovascular Events (MACE), including myocardial infarction, stroke, and cardiovascular mortality, but is associated with a higher risk of major bleeding and dyspnea. Conversely, aspirin-clopidogrel is considered safer and more affordable, although its effectiveness is relatively moderate. Therefore, the choice of DAPT should be individualized according to thrombotic and bleeding risks as well as patients’ economic conditions, to ensure appropriate therapy particularly in developing countries such as Indonesia.

References

Alkhalil, M. and Kuzemczak, M. (2021) ‘Letter by Alkhalil and Kuzemczak Regarding Article, “comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients from 12 Randomized Trials”’, Circulation, 143(6),pp.E234–E235.Availableat: https://doi.org/10.1161/CIRCULATIONAHA.120.050967.

Angiolillo, D.J. et al. (2019) ‘De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis’, Journal of Thrombosis and Thrombolysis, 48(1), pp. 1–10. Available at: https://doi.org/10.1007/s11239-019-01860-7.

Arslan, F. et al. (2021) ‘2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation: Recommendations and critical appraisal from the Dutch ACS and Interventional Cardiology working groups’, Netherlands Heart Journal, 29(11), pp. 557–565. Available at: https://doi.org/10.1007/s12471-021-01593-4.

Booth, A. (2016) ‘Searching for qualitative research for inclusion in systematic reviews : a structured methodological review’, Systematic Reviews, pp. 1–23. Available at: https://doi.org/10.1186/s13643-016-0249-x.

Chowdhury, S. and Chakraborty, P. pratim (2017) ‘Universal health coverage ‑ There is more to it than meets the eye’, Journal of Family Medicine and Primary Care, 6(2), pp. 169–170. Available at: https://doi.org/10.4103/jfmpc.jfmpc.

Collet, J.P. et al. (2021) ‘2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation’, European Heart Journal, 42(14), pp. 1289–1367. Available at: https://doi.org/10.1093/eurheartj/ehaa575.

Gimbel, M.E., Minderhoud, S.C.S. and ten Berg, J.M. (2018) ‘A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment’, Netherlands Heart Journal, 26(6), pp. 341–351. Available at: https://doi.org/10.1007/s12471-018-1117-1.

Del Giovane, C. et al. (2021) ‘Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis’, BMC Neurology, 21(1). Available at: https://doi.org/10.1186/s12883-021-02341-2.

Halkar, M. and Lincoff, A.M. (2016) ‘Dual antiplatelet therapy for acute coronary syndromes: How long to continue?’, Cleveland Clinic Journal of Medicine, 83(9), pp. 675–688. Available at: https://doi.org/10.3949/ccjm.83a.15092.

Jeyabalan, A. et al. (2025) ‘Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis’, Plos One, 20(6 June), pp. 1–56. Available at: https://doi.org/10.1371/journal.pone.0323530.

Kornowski, R. et al. (2024) ‘Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk’, Journal of the American Heart Association, 13(2), pp. 1–10. Available at: https://doi.org/10.1161/JAHA.122.029051.

Kuzmina, I.M. et al. (2021) ‘Antiplatelet Therapy in Acute Coronary Syndrome’, Russian Sklifosovsky Journal of Emergency Medical Care, 10(4), pp. 769–777. Available at: https://doi.org/10.23934/2223-9022-2021-10-4-769-777.

Muka, T. et al. (2020) ‘A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research’, European Journal of Epidemiology, 35(1), pp. 49–60. Available at: https://doi.org/10.1007/s10654-019-00576-5.

O’Donoghue, M.L., Murphy, S.A. and Sabatine, M.S. (2020) ‘The safety and efficacy of aspirin discontinuation on a background of a P2Y12inhibitor in patients after percutaneous coronary intervention: A systematic review and meta-analysis’, Circulation, 142(6), pp. 538–545. Available at: https://doi.org/10.1161/CIRCULATIONAHA.120.046251.

Page, M.J. et al. (2021) ‘The PRISMA 2020 statement: An updated guideline for reporting systematic reviews’, Bmj, 372. Available at: https://doi.org/10.1136/bmj.n71.

Rethlefsen, M.L. et al. (2021) ‘PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.’, Systematic reviews, 10(1), p. 39. Available at: https://doi.org/10.1186/s13643-020-01542-z.

Snyder, H. (2019) ‘Literature review as a research methodology: An overview and guidelines’, Journal of Business Research, 104, pp. 333–339. Available at: https://doi.org/https://doi.org/10.1016/j.jbusres.2019.07.039.

Valgimigli, M. et al. (2021) ‘Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.’, The New England journal of medicine, 385(18), pp. 1643–1655. Available at: https://doi.org/10.1056/NEJMoa2108749.

Wallentin, L. et al. (2009) ‘Ticagrelor versus clopidogrel in patients with acute coronary syndromes.’, The New England journal of medicine, 361(11), pp. 1045–1057. Available at: https://doi.org/10.1056/NEJMoa0904327.

Watanabe, Hirotoshi et al. (2022) ‘Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.’, JAMA cardiology, 7(4), pp. 407–417. Available at: https://doi.org/10.1001/jamacardio.2021.5244.

World Health Statistics (2021) World Health Statistics.

Yusuf, S. et al. (2001) ‘Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.’, The New England journal of medicine, 345(7), pp. 494–502. Available at: https://doi.org/10.1056/NEJMoa010746.

Zhao, Y. et al. (2024) ‘Effect of ticagrelor versus clopidogrel after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome—propensity score matching analysis’, BMC Cardiovascular Disorders, 24(1), pp. 1–10. Available at: https://doi.org/10.1186/s12872-023-03659-0.